BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Graham Capital Management, L.P. 2,262$784,0000.03%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 80,346$27,851,0000.03%
First PREMIER Bank 300$104,0000.03%
Simplicity Solutions, LLC 690$239,0000.03%
AQR Capital Management 40,522$13,843,0000.03%
NorthRock Partners, LLC 848$294,0000.03%
AVIVA PLC 16,920$5,865,0000.03%
Legal & General Group Plc 251,201$87,076,0000.03%
NORTHERN TRUST CORP 413,918$143,480,0000.03%
State of New Jersey Common Pension Fund D 22,521$7,807,0000.03%
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO 20,357$7,057,0000.03%
YOUSIF CAPITAL MANAGEMENT, LLC 6,482$2,247,0000.03%
Gotham Asset Management, LLC 2,647$918,0000.03%
Virtu Financial LLC 981$340,0000.03%
CAPTRUST FINANCIAL ADVISORS 12,781$4,430,0000.03%
US BANCORP \DE\ 43,012$14,910,0000.03%
TEXAS PERMANENT SCHOOL FUND CORP 5,181$1,796,0000.03%
American Portfolios Advisors 1,983$687,3870.03%
SECURIAN ASSET MANAGEMENT, INC 3,380$1,172,0000.03%
AMERICAN INTERNATIONAL GROUP, INC. 11,575$4,012,0000.03%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.